"Both p210 and p190" in which %? Generally, p210 is predominant (1-2% of all CP patients may exhibit this association). However, there are data supporting a worse prognosis for patients bearing the association.

Generally, those who progress do so in the early days.

To be practical, in terms of management, there is no strong data in favour of second gen TKIs vs imatinib. Monitoring is as per p210 only patient.

Hello,

Recently we have come across a patient with both p210 and p190 transcripts at diagnosis.

What is your experience with a case like this and its molecular monitoring and management considerations?

Awaiting your reply.

Best regards - Udani (Registrar in Haematology, Sri Lanka)